News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
180,505 Results
Type
Article (30269)
Company Profile (28)
Press Release (150208)
Section
Business (47704)
Career Advice (1769)
Deals (9643)
Drug Delivery (119)
Drug Development (30794)
Employer Resources (190)
FDA (6372)
Job Trends (5537)
News (94236)
Policy (12477)
Tag
Academia (1577)
Alliances (13081)
Alzheimer's disease (716)
Antibody-drug conjugate (ADC) (83)
Approvals (6276)
Artificial intelligence (87)
Bankruptcy (110)
Best Places to Work (4283)
Biosimilars (72)
Breast cancer (84)
Cancer (585)
Cardiovascular disease (73)
Career advice (1483)
CAR-T (66)
Cell therapy (144)
Clinical research (23399)
Collaboration (187)
COVID-19 (2229)
Data (459)
Diabetes (103)
Diagnostics (2022)
Drug pricing (104)
Earnings (16289)
Employer resources (163)
Events (22265)
Executive appointments (84)
FDA (6550)
Funding (147)
Gene therapy (144)
GLP-1 (598)
Government (3194)
Healthcare (6333)
Infectious disease (2289)
Inflammatory bowel disease (80)
Interviews (349)
IPO (3872)
Job creations (1338)
Job search strategy (1205)
Layoffs (446)
Legal (2430)
Lung cancer (101)
Lymphoma (48)
Management (64)
Manufacturing (110)
Medical device (3791)
Medtech (3792)
Mergers & acquisitions (5788)
Metabolic disorders (352)
Neuroscience (903)
NextGen Class of 2024 (2456)
Non-profit (1984)
Northern California (468)
Obesity (234)
Opinion (213)
Patents (59)
People (13269)
Phase I (6651)
Phase II (9997)
Phase III (9525)
Pipeline (227)
Podcasts (94)
Policy (94)
Postmarket research (980)
Preclinical (2512)
Radiopharmaceuticals (68)
Rare diseases (163)
Real estate (1607)
Recruiting (72)
Regulatory (7802)
Research institute (1239)
Resumes & cover letters (279)
Southern California (390)
Startups (1314)
The Weekly (59)
United States (3882)
Vaccines (577)
Weight loss (217)
Date
Today (43)
Last 7 days (217)
Last 30 days (861)
Last 365 days (11141)
2024 (10807)
2023 (12481)
2022 (16428)
2021 (17480)
2020 (16949)
2019 (15737)
2018 (12789)
2017 (9186)
2016 (8556)
2015 (9260)
2014 (6552)
2013 (5080)
2012 (5344)
2011 (5606)
2010 (5007)
Location
Africa (440)
Asia (10868)
Australia (2041)
California (1027)
Canada (367)
China (87)
Connecticut (64)
Europe (28305)
Florida (113)
Illinois (106)
Indiana (84)
Maryland (224)
Massachusetts (750)
New Jersey (318)
New York (298)
North Carolina (163)
Northern California (468)
Ohio (48)
Pennsylvania (178)
South America (504)
Southern California (390)
Texas (126)
Washington State (98)
180,505 Results for "gi windows".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Genetic Immunity (GI) Leverages VectorBuilder Partnership to Power Phase 3 HIV Vaccine Trials
December 3, 2024
·
3 min read
Business
Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update
Motus GI Holdings, Inc. reported its financial results for the first quarter ended March 31, 2024, and provided a corporate update.
May 14, 2024
·
7 min read
50% ORR: Impressive Clinical Trial Data for Irpagratinib Combined with Atezolizumab in Advanced Hepatocellular Carcinoma Stuns ESMO-GI Congress
Abbisko Therapeutics Co., Ltd. announced that it has presented new phase II clinical data of its highly selective FGFR4 inhibitor irpagratinib in combination with atezolizumab for the treatment of advanced hepatocellular carcinoma(HCC)at the 2024 ESMO-GI Congress.
June 27, 2024
·
3 min read
Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI
Medivir AB presented positive new data from its ongoing phase Ib / IIa study of fostroxacitabine bralpamide + Lenvima® in advanced hepatocellular carcinoma at the ESMO GI Cancers Congress in Munich, Germany.
June 27, 2024
·
6 min read
Genetown
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced initial data from the Phase 1 MINOTAUR study evaluating lunresertib (RP-6306) in combination with FOLFIRI for the treatment of advanced solid tumors has been selected for a poster presentation at the European Society of Medical Oncology (ESMO) Gastrointestinal (GI) Cancers Congress 2024, being held June 26-29.
May 29, 2024
·
1 min read
Business
Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today reported its financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.
March 18, 2024
·
9 min read
Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract
Motus GI Holdings, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent (patent # 11904085) titled, “Colon Cleaning System with Automatic Self-Purging Feature.”
February 21, 2024
·
3 min read
Drug Development
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX) today announced that regulators in Australia and Canada have cleared the Company’s request to expand its Phase 1b/2a RESOLVE trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (“EoE”).
May 23, 2024
·
10 min read
Medtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care
Medtronic plc announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care.
April 10, 2024
·
5 min read
BioMidwest
University Cancer & Blood Center and University Health Alliance open High-Risk GI Clinic to address community needs
University Cancer & Blood Center, a leading oncology and hematology practice for Northeast Georgia, and University Health Alliance, a multi-disciplinary practice focusing on prevention and coordinated care, announce the opening of their High-Risk GI Clinic.
April 10, 2024
·
3 min read
1 of 18,051
Next